021-51111890
购物车（）
sales@molnova.cn
MEN 11270
CAS No. 235082-52-7
MEN 11270 ( —— )
产品货号. M30640 CAS No. 235082-52-7
Peptide antagonist of the B2 bradykinin receptor (pKi = 10.3); conformationally constrained cyclized analog of HOE 140. Blocks hypotension and bronchoconstriction in vivo. Displays selectivity for B2 over 29 other receptors and ion channels (pIC50 < 5.5).
纯度: >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| 规格 | 价格/人民币 | 库存 | 数量 |
| 5MG | ￥1930 | 有现货 |
|
| 100MG | 获取报价 | 有现货 |
|
| 200MG | 获取报价 | 有现货 |
|
| 500MG | 获取报价 | 有现货 |
|
生物学信息
-
产品名称MEN 11270
-
注意事项本公司产品仅用于科研实验，不得用于人体或动物的临床与诊断
-
产品简述Peptide antagonist of the B2 bradykinin receptor (pKi = 10.3); conformationally constrained cyclized analog of HOE 140. Blocks hypotension and bronchoconstriction in vivo. Displays selectivity for B2 over 29 other receptors and ion channels (pIC50 < 5.5).
-
产品描述Peptide antagonist of the B2 bradykinin receptor (pKi = 10.3); conformationally constrained cyclized analog of HOE 140. Blocks hypotension and bronchoconstriction in vivo. Displays selectivity for B2 over 29 other receptors and ion channels (pIC50 < 5.5).
-
体外实验——
-
体内实验——
-
同义词——
-
通路GPCR/G Protein
-
靶点Bradykinin Receptor
-
受体——
-
研究领域——
-
适应症——
化学信息
-
CAS Number235082-52-7
-
分子量1299.56
-
分子式C60H90N20O11S
-
纯度>98% (HPLC)
-
溶解度30% acetonitrile / water:1 mg/mL
-
SMILES[H]N[C@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1CCC[C@H]1C(=O)N1C[C@H](O)C[C@H]1C(=O)NCC(=O)N[C@H](CC1=CC=CS1)C(=O)N[C@H]1CCNC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H]2CC3CCCCC3N2C(=O)[C@H]2CC3=CC=CC=C3CN2C1=O
-
化学全称——
运输与储存
-
储存条件(-20℃)
-
运输条件With Ice Pack
-
稳定性≥ 2 years
参考文献
1. Meini et al (1999) MEN 11270, a novel selective constrained peptide antagonist with high affinity at the human B2 kinin receptor. J.Pharmacol.Exp.Ther. 289 1250 PMID:
产品手册
关联产品
-
Bradykinin (acetate)
缓激肽（乙酸盐）是一种由激肽释放酶-激肽系统产生的活性肽。它是一种炎症介质，也被认为是多种血管和肾功能的神经介质和调节剂。它是由血液中的激肽酶产生的，是一种强大的血管扩张剂，可引起平滑肌收缩，并可能介导炎症。
-
Safotibant
Safotibant (LF-22-0542) is a bradykinin B1 receptor antagonist with anti-inflammatory and analgesic activity for the topical treatment of diabetic macular edema.
-
Sar-[D-Phe8]-des-Arg...
Potent and selective bradykinin B1 receptor agonist (EC50 = 9.02 nM in rabbit aorta) that is resistant to aminopeptidase, kininase I and II (ACE) and neutral endopeptidase cleavage. Exhibits hypotensive and angiogenic activity in vivo.
